Skip to main content
SpringerLink
Log in

Current Developments in Anticoagulant and Antithrombotic Agents

  • Chapter
Handbook of Platelet Physiology and Pharmacology

  • 303 Accesses

Abstract

Thrombosis is clearly the most common cause of death in the United States. About two million individuals die each year from an arterial or venous thrombosis or the consequences of these disorders. About 80% to 90% of all causes of thrombosis can now be defined with respect to cause. Of these, over 50% of all patients harbor a congenital or acquired blood coagulation protein or platelet defect which caused the thrombotic event. It is obviously of major importance to define those individuals harboring such a defect, as this allows (1) appropriate antithrombotic therapy to decrease risks of recurrence (2) determine length of time the patient must remain on therapy for secondary prevention and (3) allow for testing of family members in those harboring a blood coagulation protein or platelet defect which is hereditary (about 50% of all coagulation and platelet defects mentioned above). Aside from mortality, significant additional morbidity occurs from both arterial or venous thrombotic events, including, but not limited to paralysis (non-fetal thrombotic stroke), cardiac disability (repeated coronary events), loss of vision (retinal vascular thrombosis) and fetal waste syndrome (placental vascular thrombosis), stasis ulcers and other manifestations of post-phlebitic syndrome, etc.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Fareed J, Walenga JM, Pifarre R: Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surgery: State of the Art Reviews (1992) 6(1):101–111.

    Google Scholar 

  2. Fareed J, Bacher P, Messmore HL, Walenga JM, Hoppensteadt DA, Strano A, Pifarre R: Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Prog Cardiovas Dis (1992) 6:379–398.

    Article  Google Scholar 

  3. Fareed J, Walenga JM, Hoppensteadt D, Racanelli A, Coyne E: Chemical and biochemical heterogeneity in low molecular weight heparins: Implications for clinical use and standardization. Semin Thromb Hemost (1989) 15:440–463.

    Article  CAS  Google Scholar 

  4. Hull R, Raskob G, Pineo G: Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Eng J Med (1992) 326(15): 975–982.

    Article  CAS  Google Scholar 

  5. Prandoni P, Lensing A, Buller H, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW: Comparison of subcutaneous standard low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 339:441–445.

    Article  CAS  Google Scholar 

  6. Hirsh J, Levine M: The development of low molecular weight heparins for clinical use. In Verstraete M, et al. (Eds) Thrombosis and Haemostasis, pp. 425–448, Leuven University Press, Leuven, 1987

    Google Scholar 

  7. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie G, McLaughlin D: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Eng J Med (1983) 306:954–958.

    Google Scholar 

  8. Kelton JG: Heparin induced thrombocytopenia. Haemostasis (1986) 16:173–186.

    CAS  Google Scholar 

  9. Silver D, Kapsch D, Tosi E: Heparin induced thrombocytopenia, thrombosis and haemorrhage. Ann Surg (1983) 198:301–305.

    Article  CAS  Google Scholar 

  10. Griffith GC, Nichols G Jr, Asher JD, Flanagan B: Heparin osteoporosis. J Am Med Assoc (1965) 193:85–88.

    Article  Google Scholar 

  11. Bara L, Billaud E, Gramond G, Kher A, Samama M: Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res (1985) 39:631–636.

    Article  CAS  Google Scholar 

  12. Bergqvist D, M@tzsch T, Burmark US, Frisell J, Guilbaud O, Hallbk J, Horn A, Lindhagen A, LjungNr H, Ljungstr’m KG, Onarheim H, Risberg B, T’rngren S, _rtenwall P: Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg (1988) 75(9):888–891.

    Article  CAS  Google Scholar 

  13. Bonis LC, Hauch O, Jorgensen LN, Lassen MR: Enoxaparin versus dextran 70 in the prevention of postoperative deep vein thrombosis after total hip replacement. A Danish multicenter study. Proceeding of the Danish Enoxaparin Symposium, Feb 3, 1990

    Google Scholar 

  14. European Fraxiparin Study Group: Comparison of low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis is patients undergoing abdominal surgery. Br J Surg (1988) 75:1058–1063.

    Article  Google Scholar 

  15. Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F, Blumel G: Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittel-Forschung (1987) 37(7):839–843.

    CAS  Google Scholar 

  16. Baumgartner A, Jacot N, Moser G, Krahenbuhl B: Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa (1989) 18(2): 152–156.

    CAS  Google Scholar 

  17. Caen JP: A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemost (1988) 59(2):216–220.

    CAS  Google Scholar 

  18. Hartl P, Brucke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery Comparison between standard heparin and Fragmin. Thromb Res (1990) 57(4):577–584.

    Article  CAS  Google Scholar 

  19. Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risherg B: Tlirombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg (1988) 75(11): 1053–1057.

    Article  CAS  Google Scholar 

  20. Leyvraz PF, Richard J, Bachmarm F, Van Melle G, Treyvaud JM, Livio JJ, Candardjis G: Adjusted versus fixed subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Eng J Med (1983) 309:954–958.

    Article  CAS  Google Scholar 

  21. Matzsch T, Bergqvist D, Fredin H, Hedner U: Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chirur Scand (1988) 543:80–84.

    CAS  Google Scholar 

  22. Kakkar W, Murray WJG: Efficacy and safety of low molecular weight heparin (CY 216) in preventing postoperative venous thrombo-embolism A cooperative study. Br J Surg (1985) 72:786–791.

    Article  CAS  Google Scholar 

  23. Levine MN, Hirsh J: An overview of clinical trials with low molecular weight heparin fractions. Acta Chirur Scand (1988) 154(543):73–39.

    Google Scholar 

  24. Koppenhagen K, Adolf J, Matines M, Troster E, Roder JD, Haas S, Fritsche HM, Wolf H: Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost (1992) 67(6):627–630.

    CAS  Google Scholar 

  25. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenz J, Schmid KM, Betz E, Karsch KR: Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circulation (1992) 85:1548–1556.

    Article  CAS  Google Scholar 

  26. Hoppensteadt D, Racanelli A, Walenga JM, Fareed J: Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Semin Thromb Hemost (1989) 15:378–385.

    Article  CAS  Google Scholar 

  27. Marcum JA, Rosenberg RD: Role of endothelial cell surface heparin-like polysaccharides. In Heparin and related polysaccharides. Structure and activities. Eds. Ofosu FA, Danishefsky I, Hirsh J. The New York Academy of Sciences, NY 1989, pp. 81–94

    Google Scholar 

  28. Sirtori CR: Pharmacology of sulfomucopolysaccharides in atherosclerosis prevention and treatment. In Ricci G, et al, Eds Selectivity and Risk-Benefit Assessment of Hyperlipidemia Drugs. Raven Press, New York, pp 189–194, 1982

    Google Scholar 

  29. Fareed J, Hoppensteadt D, Jeske W, Walenga JM: An overview of non-heparin glycosaminoglycans as antithrombotic agents. In Blood Coagulation (1993). Poller L (ed), Churchill Livingstone, New York.

    Google Scholar 

  30. Agrati AM, DeBartolo G, Palmieri G: Heparan sulfate Efficacy and safety in patients with chronic venous insufficiency. Minerva Cardioangiologica (1991) 39(10):395–400.

    CAS  Google Scholar 

  31. Caramelli L, Mirchioni R, Carini: Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations. Rivista Europea per le Scienze Mediche e Farmacologiche (1988) 10(1):55–58.

    CAS  Google Scholar 

  32. Bergqvist D, Kettunen K, Fredin H, Fauno P, Suomalainen O, Soimaakallio S, Karjalainen P, Cederholm C, Jensen LJ, Justesen T, Stiekema JCJ: Thromboprophylaxis in patients with hip fractures A prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery (1991) 109(5):617–622.

    CAS  Google Scholar 

  33. Romeo S, Grasso A, Costanzo C: A controlled clinical experiment “within subjects” with heparan sulfate in intermittent claudication. Minerva Cardioangiol (1991) 39(9):345–352. 992) 339(8789):3340335.

    Google Scholar 

  34. Lane DA, Ryan K, Ireland H, Curtis JR, Nurmohamed MT, Krediet RT, Roggekamp MC. Stevens P, ten Cate JW: Dermatan sulphate in haemodialysis. Lancet (1 thrombocytopenia and thrombosis. Australian & New Zealand J Med (1991) 21(1):52–54.

    Google Scholar 

  35. Cofrancesco E, Boschetti C, Leonardi P, Cortellaro M: Dermatan sulphate in acute leukaemia. Lancet (1992) 339(8802):11177–11178.

    Article  Google Scholar 

  36. Fareed J, Walenga JM, Iyer L, Hoppensteadt D, Pifarre R: An objective perspective on recombinant hirudin A new anticoagulant and antithrombotic agent. Blood Coag Fiorino (1991) 2:135–147.

    Article  CAS  Google Scholar 

  37. Hijikata-Okunomiya A, Okamoto S: A strategy for a rational approach to designing synthetic selective inhibitors, Sem Thromb Hemost (1992) 18(1): 135–149.

    Article  CAS  Google Scholar 

  38. Tamao Y, Yamamoto T, Hirata T, Kinugasa M, Kimumoto M: Effect of argipidine (MD-805) on blood coagulation. Jpn Pharmacol Ther (1986) 14:869–874.

    Google Scholar 

  39. Maruyama I: Synthetic anticoagulants. Jpn J Clin Hematol (1990) 31:776–781.

    CAS  Google Scholar 

  40. Kumon K, Tanaka K, Nakajima N, Naito Y, Fijuta T: Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med (1984) 12:1039–1043.

    Article  CAS  Google Scholar 

  41. Matsuo T, Kario K, Kodama K, Okamoto S: Clinical applications of the synthetic thrombin inhibitor, Argatroban (MD-805). Sem Thromb Hemost (1992) 18(2): 155–160.

    Article  CAS  Google Scholar 

  42. Teger-Nilsson A, Eriksson U, Gustafsson D, Bylund R, Fager G, Held P: Phase I studies on Inogatran, a new selective thrombin inhibitor. J Am Col Cardiol (1995) 117A–118A.

    Google Scholar 

  43. Bajusz S, Barab<s E, SzJll E, Bagdy D: Peptide aldehyde inhibitors of the fibrinogen-thrombin reaction. In Peptides-Chemistry, Structure and Biology. Meienhofer J, ed. Ann Arbor Sci. Publ. Inc.m Ann Arbor, MI. 1975 pp603–608.

    Google Scholar 

  44. Bajusz S, SzJll E, Bagdy D, Barabas E, Horvath E, Dioszegi M, Fittler Z, Szabo G, Juhasz A, Tomori E, Szilagyi G: Highly active and selective anticoagulants D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem (1990) 33:1729–1735.

    Article  CAS  Google Scholar 

  45. Markwardt F, Fink G, Kaiser B, Klocking HP, Nowak G, Richter M, Sturzebecher J: Pharmacological survey of recombinant hirudin. Pharmazie (1988) 43:202–207.

    CAS  Google Scholar 

  46. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW 2nd: Design and characterization of hirulogs A novel class of bivalent peptide inhibitors of thrombin. Biochemistry (1990) 29:7095–7101.

    Article  CAS  Google Scholar 

  47. Iyer L, Fareed J: Recombinant hirudin: a perspective. Exp Opin Invest Drugs (1996) 5(5):469–494.

    Article  CAS  Google Scholar 

  48. Topol EJ: Novel antithrombotic approaches to coronary artery disease. Am J Cardiol (1995) 76(6):27B–33B.

    Article  Google Scholar 

  49. Riess FC, Lower C, Seelig C, Bleese N, Kormann J, Muller-Berghaus G, Potzsch B: Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg (1995) 110:265–267.

    Article  CAS  Google Scholar 

  50. Edmunds LH: HIT, HITT and desulfatohirudin: look before you leap. J Thorac Cardiovasc Surg (1995) 110(1):1–3.

    Article  Google Scholar 

  51. Kowal-Vem A, Gamelli RL, Walenga JM, Hoppensteadt D, Sharp-Pucci M, Schumacher HR: The effect of burn wound size on hemostasis a correlation of the hemostatic changes to the clinical state. Journal of Trauma (1992) 33(1):50–57.

    Article  Google Scholar 

  52. Morris, CL, Lutes R, Gruppo RA, Hashmi R, Harris R, Sambrano J, Morris JD: Prophylactic continuous infusion (CI) antithrombin III (AT-III) for prevention of regimen related toxicity (RRT) following bone marrow transplantation (BMT). Blood (1996) 88(10)(Suppl 1):117a.

    Google Scholar 

  53. Haire WD, Stephens LC, Ruby EI: Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT)-results of a pilot study. Blood (1996) 88(10)(Suppl 1):456a.

    Google Scholar 

  54. Clagett GP, Anderson Jr FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest (1995) 108(4)(Suppl):312S–334S.

    Article  CAS  Google Scholar 

  55. Sthrzebecher J, Sthrzebecher U, Vieweg H, Wagner G, Hauptmann J, Markwardt F. Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency. Thromb Res (1989) 54:245–252.

    Article  Google Scholar 

  56. Hauptmann J, Kaiser B, Nowak G, Sthrzebecher J, Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost (1990) 63:220–223.

    CAS  Google Scholar 

  57. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med (1996) 335(11):775–782.

    Article  Google Scholar 

  58. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation (1996) 94:911–921.

    Article  CAS  Google Scholar 

  59. Kaiser B, Hauptmann J. Factor Xa inhibitors as novel antithrombotic agents: Facts and perspectives. Cardiovascular Drug Reviews (1994) 12(3):225–236.

    Article  CAS  Google Scholar 

  60. Kaiser B. Factor Xa versus factor IIa inhibitors. Clin Appl Thrombosis/Hemostasis (1997) 3(1): 16–24.

    Article  Google Scholar 

  61. Saltiel E, Ward A: Ticlopidins review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs (1987) 34:222–262.

    Article  CAS  Google Scholar 

  62. Pytele R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslathi E: Platelet membrane glycoprotein Iib/IIIamember of a family od RGD specific adhesion receptors. Science (1986) 231:1559–1562.

    Article  Google Scholar 

  63. Philips DR, Charo IF, Scarborough RM: GPIIb-IIIathe responsive integrin. Cell (1991) 65:359–362.

    Article  Google Scholar 

  64. Ruggeri ZM, Houghton RA, Russel SR, Zimmerman TS: Inhibition of platelet function with synthetic peptide designed to be high affinity antagonist of fibrinogen binding to platelets. Proc Natl Acad Sci USA (1986) 83:5708–5712.

    Article  CAS  Google Scholar 

  65. Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR: Antiplatelet antibody [7E3 f(ab’)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation (1990) 81:617–627.

    Article  CAS  Google Scholar 

  66. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355(6360): 564–566.

    Article  CAS  Google Scholar 

  67. Macaya RF, Schultze P, Smith FW, Roe JA, Feigon J: Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA (1993) 90:3745–3749.

    Article  CAS  Google Scholar 

  68. Paborsky LR, McCurdy SN, Griffin LC, Toole JJ, Leung LLK: The single-stranded DNA aptamer binding-site of human thrombin. J Biol Chem (1993) 268:20808.

    CAS  Google Scholar 

  69. Kubik MF, Stephens AW, Schneider D, Marlar R, Tasset D: High-affinity RNA ligands to human ”-thrombin. Nucleic Acids Research (1994) 22(13): 2619–2626.

    Article  CAS  Google Scholar 

  70. Fareed J, Walenga JM, Hoppensteadt DA, Kumar A, Ulutin O, Cornelli U: Pharmacologic profiling of defibrotide in experimental models. Semin Thromb Hemost (1988) 14:27–37.

    Google Scholar 

  71. Bracht F, Schror K: Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Com (1994) 200(2):933–937.

    Article  CAS  Google Scholar 

  72. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindratt S, Close P: A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med (1997) 337:1329–1335.

    Article  CAS  Google Scholar 

  73. Kaiser B, Callas D, Walenga JM, Fareed J: Synthetic and recombinant antithrombin drugs. Exp Opin Invest Drugs (1998) 7(6):963–985.

    Article  CAS  Google Scholar 

  74. Kaiser. Hoppensteadt D, Fareed J: Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. Exp Opin Invest Drugs (1998) 7(7): 1–20.

    Google Scholar 

  75. Gewirtz AM, Sokol DL, Ratajczak MZ: Nucleic acid therapeutics: State of the art and future prospects. Blood (1998) 92:712–736.

    CAS  Google Scholar 

  76. Richardson P, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, earman SI, Iacobelli M, Fareed J, Guinan EC: Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood (1998) 92:737–744.

    CAS  Google Scholar 

  77. Zachaarski LR, Ornstein DL: Heparin and cancer. Hemostasis Thromb (1998) 80:10–23.

    Google Scholar 

  78. Fareed J, Callas D, Hoppensteadt DA, Walenga JM, Bick RL: Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Medical Clinics of North America (1998) 82(3):569–586.

    Article  CAS  Google Scholar 

  79. Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick RL: Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clinical Chemistry (1998) 44:8(B): 1845–1853.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology and, Thoracic and Cardiovascular Surgery, Loyola University Health Systems, USA

    Jawed Fareed Ph.D. FACB., Debra Hoppensteadt Ph.D., DIC., Daniel Fareed B. Sc., Jeanine M. Walenga Ph.D., Helmut Wolf M.D., Ph.D. & Rodger L. Bick M.D., Ph.D.

Authors
  1. Jawed Fareed Ph.D. FACB.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Debra Hoppensteadt Ph.D., DIC.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Fareed B. Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeanine M. Walenga Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helmut Wolf M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rodger L. Bick M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Lab. Med. & Pathol. and Biomed. Engineering, UMHC, P. B. 609, USA

    Gundu H. R. Rao Ph. D.

  2. Academic Health Center, University of Minnesota, Minneapolis, MN, 55455, USA

    Gundu H. R. Rao Ph. D.

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fareed, J., Hoppensteadt, D., Fareed, D., Walenga, J.M., Wolf, H., Bick, R.L. (1999). Current Developments in Anticoagulant and Antithrombotic Agents. In: Rao, G.H.R. (eds) Handbook of Platelet Physiology and Pharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5049-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5049-5_23

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7295-0

  • Online ISBN: 978-1-4615-5049-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation